Clinical Trials Sponsored by Thync Global, Inc.

Total 301 results

Thync Global, Inc.
ethica Clinical Research Inc.

Completed

12-Week Study Assessing Change in Psoriasis Severity and Level of Stress Using TEN

Stress | Psoriasis

United States
Thync Global, Inc.
ethica Clinical Research Inc.

Unknown

Efficacy and Safety Study of Autonomic Nerve Modulation (ANM) in Subjects With Moderate Plaque Psoriasis

Plaque Psoriasis

United States
Novan, Inc.
WCCT Global

Completed

Pharmacokinetics of Topical SB204 in Adolescents With Acne Vulgaris

Acne Vulgaris

United States
Pulmotect, Inc.
WCCT Global

Completed

Effect of Pre-Treatment With Cromolyn or Albuterol on Response to PUL-042 Inhalation Solution (PUL-042)

Healthy

United States
FemmePharma Global Healthcare, Inc.

Completed

An Open-Label, MultiCenter Evaluation of the Use of Topically Administered FP1198 in Subjects With Pain Associated With Cyclic Mastalgia

Moderate to Severe Cyclic Mastalgia

United States
FemmePharma Global Healthcare, Inc.

Completed

A Study of Topical Danazol for the Treatment of Pain Associated With Fibrocystic Breast Disease (FP1198-001)

Fibrocystic Disease of Breast

United States
MicroTransponder Inc.
ResearchPoint Global

Completed

Pivotal Study of VNS During Rehab After Stroke (VNS-REHAB) (VNS-REHAB)

Upper Extremity Paresis | Cerebrovascular Stroke

United States, United Kingdom
FemmePharma Global Healthcare, Inc.

Completed

A Study of Oxybutynin for the Treatment of Urge Urinary Incontinence (FP1097-002)

Urinary Incontinence, Urge

United States
Immunomolecular Therapeutics, Inc.
WCCT Global

Completed

Multiple Ascending Dose (MAD) Study of IMT-002 in HLA-DQ8-positive Type 1 Diabetes

Type1 Diabetes

United States
OPKO Health, Inc.
WCCT Global

Completed

Pharmacokinetics and Pharmacodynamics of Long Acting Human Growth Hormone (hGH) Product (MOD-4023) in Healthy Caucasian and Japanese Volunteers

Growth Hormone Deficiency

United States
NeuroGenetic Pharmaceuticals Inc
WCCT Global

Completed

Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Volunteers (14 Day Multiple Ascending Dose)

Alzheimer's Disease

United States
HeartPoint Global
Meditrial USA Inc.

Not yet recruiting

IntelliStent Pulmonary Flow Adjustment in Congenital Heart Disease and Dilated Cardiomyopathy (HEARTFUL-CHD)

Pulmonary Arterial Hypertension | Dilated Cardiomyopathy | Congenital Heart Disease
Anthos Therapeutics, Inc.
CYTE Global

Recruiting

Study in Atrial Fibrillation (AF) Patients at High Risk of Stroke (GARDENIA)

Atrial Fibrillation

United States, Czechia, Poland, Spain, Germany, Canada, Hungary, United Kingdom, Argentina, Italy, Brazil, Mexico
AMAG Pharmaceuticals, Inc.
ResearchPoint Global

Completed

Confirmatory Study of 17P vs Vehicle for Prevention of Preterm Birth in Women w/ Previous Spontaneous Preterm Delivery (PROLONG)

Preterm Birth

United States, Spain, Russian Federation, Canada, Bulgaria, Czechia, Hungary, Italy, Ukraine
Dance Biopharm Inc.
WCCT Global

Terminated

PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD

Safety and Tolerability

United States
Global Research Institute
Rational Vaccines Inc

Recruiting

A 48 Week Observational Study of the Frequency of Symptomatic Herpes Virus I and II in HIV Infected Subjects (HSVHIV)

HIV Disease | Herpes Simplex 2 | Herpes Simplex 1

United States
Thomas Jefferson University
CVR Global, Inc.

Terminated

Evaluation of a Novel Technique to Investigate CAS Piezo Electric Sensors

Carotid Artery Disease

United States
Cytokinetics
Astellas Pharma Global Development, Inc.

Completed

A Study of CK-2127107 in Patients With Spinal Muscular Atrophy

Spinal Muscular Atrophy

United States, Canada
Astellas Pharma Global Development, Inc.

Not yet recruiting

A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas

B-cell Lymphoma
Astellas Pharma Global Development, Inc.

Recruiting

A Study of ASP1012 in Adults With Solid Tumors

Solid Tumor

United States
Astellas Pharma Global Development, Inc.

Recruiting

A Study of ASP2074 in Adults With Solid Tumors

Advanced Solid Tumors

United States, Japan
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Study of ASP1002 in Adults for Treatment of Solid Tumors

Advanced Solid Tumors

United States
Astellas Pharma Global Development, Inc.

Completed

A Study of Fezolinetant to Treat Hot Flashes in Women Going Through Menopause (Daylight)

Vasomotor Symptoms

Poland, Spain, Belgium, Canada, Czechia, Denmark, Finland, France, Germany, Hungary, Italy, Netherlands, Norway, Sweden, Turkey, United Kingdom
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Study to Assess the Safety, Tolerability and Immunological Response of ASP2390 in Adult Subjects Allergic to House Dust Mites

Allergic to House Dust Mites

Germany
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

Leukemia, Acute Myeloid (AML)

Japan, United States, Belgium, Canada, France, Germany, Israel, Italy, Korea, Republic of, Poland, Spain, Taiwan, Turkey, United Kingdom
Astellas Pharma Global Development, Inc.

Terminated

A Study to Assess ASP0598 Otic Solution Following Topical Application in the Ear in Subjects With Chronic Tympanic Membrane Perforation (CTMP)

Chronic Tympanic Membrane Perforation

United States
Astellas Pharma Global Development, Inc.

Terminated

A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB) (Dolphin)

Pharmacokinetics of Mirabegron | Overactive Bladder (OAB)

Korea, Republic of, Russian Federation, Turkey
Astellas Pharma Global Development, Inc.

Completed

Incidence and Clinical Burden of Erythropoietin Hyporesponsiveness - a Retrospective Database Analysis

Chronic Kidney Disease

Germany
Astellas Pharma Global Development, Inc.

Completed

Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants

Ovarian Cancer | NSCLC | Solid Tumors | ESCC

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Investigate the Effect of Severe Renal Impairment on Gilteritinib Compared to Healthy Participants With Normal Renal Function

Renal Impaired | Gilteritinib | Normal Renal Function | Pharmacokinetics of ASP2215

United States, Bulgaria
Astellas Pharma Global Development, Inc.

Completed

A Study to Learn How [14C]ASP0367 is Processed by the Body in Healthy Men

Healthy Volunteers

United States
Astellas Pharma Global Development, Inc.

Terminated

A Study to Find a Suitable Dose of ASP8731 and Check for Medical Problems at Each Dose in Healthy Adults

Healthy Participants

United States
Astellas Pharma Global Development, Inc.

Completed

Survey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) Study

Prostate Cancer | Metastatic Hormone-sensitive Prostate Cancer

United States
Astellas Pharma Global Development, Inc.

Withdrawn

A Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine/Naloxone in Participants With Opioid Use Disorder

Opioid Use Disorder
Astellas Pharma Global Development, Inc.

Completed

A Study to Assess Bioequivalence of Fezolinetant Formulations in Healthy Female Participants

Healthy Volunteers

United States
Astellas Pharma Global Development, Inc.

Completed

Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial

Acute Myeloid Leukemia | Advanced Solid Tumors

United States
Astellas Pharma Global Development, Inc.

Completed

To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients (ASTOUND)

Kidney Transplantation

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Assess the Relative Bioavailability of Gilteritinib Following a Single Dose of Gilteritinib Mini-tablet Oral Suspension and Gilteritinib Mini-tablets Compared to a Single Dose of Gilteritinib Tablet in Healthy Subjects

Healthy Volunteer

United States
Astellas Pharma Global Development, Inc.

Completed

A Study in Healthy Adult Volunteers to Assess the Safety and Pharmacokinetics of an Investigational Imaging Product

Healthy Subjects

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer (ASPIRE-PCa)

Prostate Cancer | Castration-resistant Prostate Cancer | Metastatic Prostate Cancer

Spain, Taiwan, France, Algeria, Argentina, Australia, Austria, Brazil, Canada, Colombia, Egypt, Germany, Indonesia, Israel, Italy, Korea, Republic of, Lebanon, Mexico, Netherlands, New Zealand, Oman, Peru, Philippines, Saudi Arabia, Sin... and more
Astellas Pharma Global Development, Inc.

Terminated

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

United States, Canada
Astellas Pharma Global Development, Inc.

Completed

Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors

Advanced Solid Tumors | Pharmacokinetics of 14C-labeled Gilteritinib

United States
Astellas Pharma Global Development, Inc.

Terminated

A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)

Non-Small-Cell Lung Cancer

Japan
Astellas Pharma Global Development, Inc.

Terminated

A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations (SOLAR)

Non-small Cell Lung Cancer (NSCLC)

United States, Australia, Belgium, Canada, Chile, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Peru, Portugal, Romania, Russian Federation, Singapore, Spain, Taiwan, Thailand, Ukraine, United Kingdom
Astellas Pharma Global Development, Inc.

Withdrawn

A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors

Solid Tumors | Epidermal Growth Factor Receptor (EGFR) Mutations
Astellas Pharma Global Development, Inc.

Completed

A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT) (EXERRT)

Coronary Artery Disease (CAD)

United States, Peru, Argentina, Puerto Rico
Astellas Pharma Global Development, Inc.

Terminated

Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of Neonatal Candidiasis (MAGIC-2)

Candidiasis

Philippines, United States, Canada, Israel, Romania, Greece, Turkey, Brazil, Bulgaria, Colombia, Hungary, Ukraine
Astellas Pharma Global Development, Inc.

Completed

A Phase I Study to Compare 3 Different Strengths of an Extended Release Formulation of ASP015K to an Immediate Release Formulation of ASP015K

Healthy Volunteers | Pharmacokinetics of ASP015K | Food Effect

United States
Astellas Pharma Global Development, Inc.

Completed

A Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of ASP2409 Following a Single Intravenous Dose in Patients With Rheumatoid Arthritis on Methotrexate

Rheumatoid Arthritis | Pharmacokinetics of ASP2409

United States
Astellas Pharma Global Development, Inc.

Completed

A Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP2408 Following Single Intravenous Doses in Healthy Subjects

Healthy Subjects | Pharmacokinetics of ASP2408

United States

Clinical Trials Sponsored by Thync Global, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations